Literature DB >> 23449114

Advances in cancer immunotherapy.

Adam E Snook1, Scott A Waldman.   

Abstract

Our immune system is characterized by remarkable specificity, potency, and memory -- the ability of a single vaccine treatment to provide life-long protection. No pharmacologic treatment for any indication can provide the same level of safety, efficacy, and long-lasting effect that a vaccine can. Thus, researchers and clinicians alike have sought to apply these characteristics to the treatment of cancer. Yet, for the last 125 years, the field has failed to realize this potential. Here, we will review some of the most promising cancer immunotherapeutic approaches in development today, as recent clinical successes signal the beginning of cancer immuno-therapy's transition from experimental to established therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449114      PMCID: PMC4066887     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  33 in total

1.  Coley toxins immunotherapy: a retrospective review.

Authors:  M A Richardson; T Ramirez; N C Russell; L A Moye
Journal:  Altern Ther Health Med       Date:  1999-05       Impact factor: 1.305

2.  Discontinued drugs in 2005: oncology drugs.

Authors:  Lloyd Kelland
Journal:  Expert Opin Investig Drugs       Date:  2006-11       Impact factor: 6.206

3.  The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

Authors:  W B Coley
Journal:  Clin Orthop Relat Res       Date:  1991-01       Impact factor: 4.176

Review 4.  Therapeutic targeting of myeloid-derived suppressor cells.

Authors:  Stefano Ugel; Federica Delpozzo; Giacomo Desantis; Francesca Papalini; Francesca Simonato; Nada Sonda; Serena Zilio; Vincenzo Bronte
Journal:  Curr Opin Pharmacol       Date:  2009-07-16       Impact factor: 5.547

5.  Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice.

Authors:  E Aboud-Pirak; E Hurwitz; M E Pirak; F Bellot; J Schlessinger; M Sela
Journal:  J Natl Cancer Inst       Date:  1988-12-21       Impact factor: 13.506

6.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

7.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Authors:  Laura A Johnson; Richard A Morgan; Mark E Dudley; Lydie Cassard; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Richard M Sherry; John R Wunderlich; Chyi-Chia R Lee; Nicholas P Restifo; Susan L Schwarz; Alexandria P Cogdill; Rachel J Bishop; Hung Kim; Carmen C Brewer; Susan F Rudy; Carter VanWaes; Jeremy L Davis; Aarti Mathur; Robert T Ripley; Debbie A Nathan; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-18       Impact factor: 22.113

8.  Clinical significance of the KRAS mutation.

Authors:  Sead Beganovic
Journal:  Bosn J Basic Med Sci       Date:  2009-10       Impact factor: 3.363

9.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Thomas J Schuetz; Brent A Blumenstein; L Michael Glode; David L Bilhartz; Michael Wyand; Kelledy Manson; Dennis L Panicali; Reiner Laus; Jeffrey Schlom; William L Dahut; Philip M Arlen; James L Gulley; Wayne R Godfrey
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

Review 10.  Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.

Authors:  Jens Ruter; Brian G Barnett; Ilona Kryczek; Michael J Brumlik; Benjamin J Daniel; George Coukos; Weiping Zou; Tyler J Curiel
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  5 in total

Review 1.  Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.

Authors:  Allison A Aka; Jeff A Rappaport; Amanda M Pattison; Takami Sato; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2017-04-10       Impact factor: 5.045

Review 2.  Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response.

Authors:  Muhammad Baghdadi; Shintaro Takeuchi; Haruka Wada; Ken-Ichiro Seino
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

3.  A novel cohort of cancer-testis biomarker genes revealed through meta-analysis of clinical data sets.

Authors:  Stephen J Sammut; Julia Feichtinger; Nicholas Stuart; Jane A Wakeman; Lee Larcombe; Ramsay J McFarlane
Journal:  Oncoscience       Date:  2014-05-06

4.  Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer.

Authors:  Tao Jiang; Xiao Chen; Wei Zhou; Guoxin Fan; Peilin Zhao; Shengxiang Ren; Caicun Zhou; Jun Zhang
Journal:  Transl Oncol       Date:  2017-01-25       Impact factor: 4.243

5.  A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells.

Authors:  Lei Qiu; Jie Li; Shichong Yu; Qianli Wang; Yinghua Li; Zhenlin Hu; Qiuye Wu; Zhongwu Guo; Junping Zhang
Journal:  Oncotarget       Date:  2015-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.